A shift in clinical practice: optimal antibiotics for golden staph bloodstream infections
A large-scale clinical trial has found that the antibiotic cefazolin is as effective as flucloxacillin for treating golden staph bloodstream infections, with fewer side effects. Researchers suggest this evidence should shift standard clinical practice.
Why it matters
Adopting cefazolin could improve patient outcomes and reduce the incidence of acute kidney injury in hospital settings.
A global clinical trial involving more than 150 hospitals has challenged the position of flucloxacillin as the default treatment for MSSA and PSSA infections.
The article is a science report based on peer-reviewed clinical trial findings published in medical journals.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in